List of Excipients in Branded Drug REGRANEX

« Back to Dashboard

REGRANEX Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

REGRANEX is a topical 0.01% becaplermin gel for certain lower-extremity diabetic ulcers. Its formulation uses a relatively simple aqueous gel system: sodium carboxymethylcellulose for viscosity, sodium acetate and acetic acid for pH control, parabens for antimicrobial preservation, and water as the vehicle. The main commercial opportunity is not a novel excipient claim alone. It is a differentiated delivery package combining protein stability, preservative control, dosing accuracy, wound compatibility, and lower-cost manufacturing.

The product’s strategic constraints are its recombinant protein active ingredient, limited indication, black-box malignancy warning, 20-week treatment limitation, and the need for controlled wound care. Excipient innovation can reduce handling and stability problems, but it cannot eliminate becaplermin’s clinical and regulatory limitations.

What is REGRANEX and how is it regulated?

REGRANEX contains becaplermin, a recombinant human platelet-derived growth factor-BB, or rhPDGF-BB. The product is supplied as a topical gel at a concentration of 0.01%, equivalent to 100 micrograms of becaplermin per gram of gel.[1]

The FDA-approved use is as an adjunct to, and not a substitute for, good ulcer-care practices. Treatment includes appropriate wound care, pressure relief, infection control, and assessment of blood supply. The labeled population is adults with adequate blood supply who have diabetic neuropathic ulcers extending into the subcutaneous tissue or beyond and measuring no more than a specified surface area.[1]

Regulatory attribute	REGRANEX position
Active ingredient	Becaplermin
Biological class	Recombinant human PDGF-BB
Dosage form	Topical aqueous gel
Strength	0.01%
Original FDA approval	1997
Application	NDA 020954
Primary use	Adjunctive treatment of selected diabetic lower-extremity ulcers
Administration	Topical, generally once daily
Treatment limit	Up to 20 weeks under labeling
Key safety restriction	Boxed warning concerning malignancy risk
Regulatory pathway	NDA product rather than a conventional small-molecule tablet or capsule

The product’s label states that becaplermin should not be used in patients with known malignancy at the application site and should be used cautiously in patients with known malignancy.[1] These restrictions influence the addressable market and raise the regulatory burden for any reformulated product.

What excipients are used in REGRANEX gel?

The commercial formulation uses a conventional aqueous polymer gel designed to keep becaplermin dispersed and available for topical application.

Excipient or component	Likely formulation function	Commercial relevance
Sodium carboxymethylcellulose	Viscosity modifier and gel-forming polymer	Controls spreadability, residence time, and dosing consistency
Sodium acetate trihydrate	Buffer component	Helps maintain pH during storage and use
Acetic acid	pH adjustment and buffer component	Controls protein stability and formulation pH
Methylparaben	Antimicrobial preservative	Supports multidose-container microbiological control
Propylparaben	Antimicrobial preservative	Provides complementary preservative coverage
Water for injection or purified aqueous vehicle	Continuous phase	Carries the protein and excipient system

The exact commercial formulation and manufacturing specifications should be evaluated against the current FDA labeling and approved chemistry, manufacturing, and controls record. DailyMed identifies the named inactive ingredients for REGRANEX and provides the current product label.[2]

Why sodium carboxymethylcellulose matters

Sodium carboxymethylcellulose is the central rheology excipient. It gives the product enough viscosity to remain on the wound surface while permitting application with a clean applicator or gloved finger. Its molecular weight, degree of substitution, hydration profile, and concentration can affect:

• Gel yield stress
• Spreadability over irregular wound surfaces
• Residual film formation
• Protein adsorption to the container
• Dose uniformity during repeated withdrawal
• Syringe or tube extrusion force

A substitute polymer could create a differentiated product, but it would also require comparative rheology, protein recovery, preservative efficacy, microbial limits, extractables and leachables, and clinical bridging.

Why the buffer system matters

Becaplermin is a recombinant protein. Its stability can be affected by pH drift, oxidation, aggregation, adsorption, and mechanical stress. The sodium acetate and acetic acid system provides pH control while avoiding a more complex excipient profile.

The commercial value of buffer optimization lies in preserving biological activity rather than simply improving appearance. A reformulation program should measure:

1. Monomer content and aggregate formation.
2. Potency in a validated cell-based or receptor-binding assay.
3. Visible and subvisible particles.
4. Adsorption to primary packaging.
5. Stability after repeated opening.
6. Stability under temperature excursions.
7. Compatibility with wound dressings.

What formulation patents protect REGRANEX?

The original REGRANEX formulation and becaplermin technology were protected by older patent families associated with recombinant PDGF production, therapeutic use, and pharmaceutical formulations. Most commercially important protection for the original product is now old relative to the 1997 approval date.

The principal current barrier is therefore unlikely to be a long, unexpired composition-of-matter patent covering the marketed gel. The practical barriers are:

• Recombinant protein production and characterization.
• Demonstration of comparable biological activity.
• Stability and aggregation control.
• Container-closure compatibility.
• Preservative efficacy.
• Clinical and regulatory requirements for a topical biologic.
• Limited commercial scale in a specialized wound-care market.

An applicant should review the current FDA Orange Book and FDA patent-listing records for NDA 020954 before relying on any patent conclusion.[3] The Orange Book is the controlling source for listed patents and regulatory exclusivity, while historical patent families may remain relevant to freedom-to-operate analysis even after Orange Book expiry.

What types of new claims could protect a REGRANEX follow-on?

A commercially useful patent estate could focus on:

• A becaplermin gel with defined viscosity and pH ranges.
• Reduced aggregation after storage.
• Improved potency retention under refrigerated or room-temperature conditions.
• Preservative-free single-use packaging.
• A specific polymer system with improved wound residence.
• Low-shear manufacturing that preserves protein activity.
• A tube, syringe, pump, or unit-dose applicator that improves dose recovery.
• A dressing-plus-gel combination.
• A method for reducing application-site waste.
• A formulation with reduced parabens or an alternative preservative system.
• A lyophilized or concentrated becaplermin product reconstituted before use.

Patent strength would depend on whether the claims capture a measurable technical effect. Broad claims to "becaplermin in a gel" would face prior-art and obviousness challenges. Narrow claims tied to a validated stability or delivery advantage would be more defensible.

How can excipient strategy create commercial opportunities?

The strongest opportunity is a reformulated product that solves a handling or adherence problem without reducing protein potency.

Preservative-free single-use packaging

The marketed multidose format creates a need for repeated opening and handling. A sterile single-use package could reduce preservative exposure and contamination concerns. Candidate formats include:

• Unit-dose syringes
• Small sterile tubes
• Blow-fill-seal containers
• Metered applicators
• Single-use sachets with wound-care kits

The tradeoff is cost. Unit-dose packaging increases fill-finish expense and packaging waste, but it may support hospital, outpatient wound clinic, and home-health channels.

Alternative preservation systems

Methylparaben and propylparaben are established preservatives, but some customers may prefer reduced-paraben or preservative-free products. Alternatives require careful evaluation because antimicrobial systems can damage proteins or cause local irritation.

Potential development paths include:

• Lower preservative concentrations supported by validated packaging and in-use data.
• A different preservative system compatible with rhPDGF-BB.
• A sterile preservative-free formulation in a closed unit-dose device.
• A low-bioburden manufacturing process paired with a single-use container.

The commercial claim should focus on demonstrated stability, tolerability, or handling improvement. "Paraben-free" alone may not justify a premium in a price-sensitive wound-care market.

Improved wound residence

A gel that remains on the wound longer could reduce application loss and improve exposure. Candidate excipient approaches include:

• Modified cellulose polymers.
• Thermoresponsive polymers.
• Mucoadhesive or tissue-adherent polymers.
• In situ gelling systems.
• Polymer blends with controlled yield stress.

These approaches introduce clinical risk. Increased residence can also increase occlusion, local irritation, dressing interaction, or unintended exposure outside the wound bed. A higher-viscosity product would need comparative clinical evidence, not only laboratory rheology.

Dose delivery and waste reduction

REGRANEX dosing is based on ulcer area and a calculated quantity of gel. This creates an opportunity for an applicator that improves measurement and limits overuse.

Commercial concepts include:

Product concept	Customer benefit	Main development risk
Metered-dose pump	Reproducible amount per actuation	Protein recovery and priming loss
Graduated syringe	Area-based dosing	Extractables, dead volume, dose accuracy
Unit-dose applicator	Lower contamination risk	Higher cost per treatment
Wound-measuring software linked to dosing	Reduces calculation error	Software and medical-device regulation
Combination kit with dressing	Simplifies workflow	Combination-product classification

A dosing device may provide stronger market differentiation than an excipient change alone.

What generic entry risks exist for REGRANEX?

REGRANEX is exposed to follow-on competition because its original approval is old and its core formulation is technically understandable. The principal entry routes are:

1. An ANDA, if FDA accepts a product as pharmaceutically equivalent and therapeutically equivalent.
2. A 505(b)(2) application for a materially different formulation, delivery system, or clinical use.
3. A biologic or biosimilar-style pathway only if the applicable regulatory classification supports that route.

Because becaplermin is a recombinant protein approved under an NDA, the competitive pathway is not identical to that for a simple topical small-molecule generic. FDA would assess active-ingredient identity, potency, impurities, aggregation, formulation, route, dosage form, and clinical performance.

Paragraph IV challenge exposure

A Paragraph IV applicant would need to challenge any Orange Book-listed patents associated with NDA 020954. The commercial incentive depends on whether listed patents remain enforceable and whether the applicant can obtain an acceptable therapeutic-equivalence rating.

A Paragraph IV strategy could target:

• Formulation claims.
• Use claims for diabetic ulcers.
• Manufacturing claims listed or relevant to the product.
• Device or package claims, if listed.
• Any later-added patents covering improved storage or delivery.

The strongest generic challenge would likely focus on sameness and regulatory acceptability rather than on a difficult active-ingredient synthesis problem. A 30-month stay could arise if a patent owner files timely infringement litigation after receiving a Paragraph IV notice, subject to the Hatch-Waxman framework.[4]

When does REGRANEX lose exclusivity?

The original product’s practical exclusivity has already matured beyond the standard five-year new chemical entity period. FDA approved REGRANEX in 1997, so the original statutory exclusivity period expired years ago.[1,5]

Exclusivity or protection type	REGRANEX position
New chemical entity exclusivity	Expired
Original approval date	1997
Pediatric exclusivity	No commercially central current barrier identified
Orange Book patent protection	Must be confirmed against the current listing
Formulation exclusivity	No broad, current exclusivity assumed
Market protection	Dependent on manufacturing, regulatory, clinical, and commercial execution

The absence of major current exclusivity does not guarantee rapid generic entry. The market is specialized, the active ingredient is a recombinant protein, and clinical demand depends on wound-care protocols. A competitor still needs a reliable supply chain and a reimbursement strategy.

Is there biosimilar risk for REGRANEX?

Biosimilar risk is limited in the conventional sense. REGRANEX is a topical recombinant protein product approved under an NDA, not a widely used systemic biologic with a mature biosimilar market.

The practical risk is a follow-on becaplermin product that demonstrates comparable activity and obtains FDA approval through an abbreviated or bridging route. Such a product could compete on price, packaging, or distribution even if it is not legally designated a biosimilar.

The key technical hurdles are:

• Matching rhPDGF-BB structure and biological activity.
• Controlling host-cell proteins, DNA, endotoxin, and aggregates.
• Demonstrating formulation compatibility.
• Establishing microbial quality for a multidose topical product.
• Showing comparable delivery to the ulcer site.
• Managing the malignancy warning and treatment-duration limitations.

What manufacturing and IP barriers protect the product?

The strongest barriers are process and quality barriers rather than basic excipient availability.

Recombinant protein manufacturing

A competitor must control cell culture, purification, folding, dimer formation, and impurity clearance. Batch-to-batch potency can be more difficult to manage than for a conventional topical active ingredient.

Protein-compatible fill-finish

Manufacturing must limit:

• Air-liquid interfaces.
• Excessive shear.
• Metal-ion exposure.
• Surface adsorption.
• Temperature excursions.
• Hold-time degradation.
• Container interaction.

Container-closure system

The package must provide adequate oxygen, moisture, light, and microbial protection while preserving protein recovery. A tube that leaves a high residual volume can create a clinically meaningful dose discrepancy, especially when ulcers are small.

Wound-care integration

A formulation may be technically superior but commercially weak if it does not work with common dressings, off-loading devices, home-health procedures, and clinic protocols. Compatibility data can support both regulatory submissions and market access.

What licensing deals and competitive products affect REGRANEX?

Publicly visible commercial competition is broader than direct becaplermin competition. REGRANEX competes with:

• Advanced wound dressings.
• Collagen-based products.
• Cellular and tissue-based products.
• Negative-pressure wound therapy.
• Topical antimicrobial and debridement products.
• Surgical and vascular interventions.
• Off-loading and diabetic-foot management programs.

The major commercial substitutes may not contain growth factors. Payers and wound centers often compare total episode-of-care cost, healing rate, recurrence, application burden, and reimbursement status.

No specific licensing transaction should be treated as a current REGRANEX commercial right without confirmation from the relevant company, FDA records, or SEC filings. The product’s licensing value would most likely arise from a regional commercialization agreement, a private-label formulation, or an improved applicator rather than from a broad platform license.

How strong is the REGRANEX patent estate?

The original estate is strategically weaker than it was during the launch period because the product has been marketed for more than two decades. A new entrant should assume that broad claims directed only to becaplermin in a topical gel will face substantial prior-art exposure.

The defensible areas are narrower:

Estate segment	Relative opportunity
Basic becaplermin composition	Low for new broad protection
Generic aqueous gel	Low
Defined stability profile	Moderate
Novel preservative-free system	Moderate to strong if technically supported
Metered delivery device	Moderate
Combination dressing	Moderate
Manufacturing process with improved potency recovery	Moderate
New clinical use	Depends on evidence and patentability
Digital dosing support	Moderate, with device and software constraints

A patent filing should be supported by comparative data against the commercial formulation. Useful evidence includes accelerated stability, real-time stability, potency retention, aggregate reduction, application recovery, wound-surface residence, and usability.

What generic launch scenarios are most likely?

Scenario 1: Low-cost conventional follow-on

A competitor reproduces the basic aqueous gel and seeks an abbreviated approval. This would create the highest price pressure but may face the greatest challenge in proving equivalence for a recombinant protein.

Scenario 2: 505(b)(2) differentiated gel

A company introduces a modified polymer, preservative system, or container and seeks approval through a bridging strategy. This route could support product differentiation but would impose higher development and clinical costs.

Scenario 3: Device-led premium product

A manufacturer retains a familiar formulation but adds a metered applicator, unit-dose format, or wound-measurement workflow. The value proposition would be lower waste, dosing accuracy, and reduced contamination risk.

Scenario 4: Integrated wound-care kit

A company combines becaplermin or a follow-on product with dressings, off-loading materials, and home-health instructions. This could improve adherence and contracting leverage but may create combination-product and reimbursement complexity.

What is the commercial opportunity for excipient suppliers?

Excipient suppliers can participate in four areas:

1. High-purity cellulose polymers with controlled rheology.
2. Protein-compatible preservative systems.
3. Low-binding or low-adsorption packaging materials.
4. Sterile unit-dose and metered-delivery components.

The most valuable supplier position is a qualified formulation-and-package platform supported by stability and compatibility data. Commodity supply of sodium carboxymethylcellulose alone is unlikely to create durable differentiation.

Key Takeaways

• REGRANEX is a 0.01% becaplermin aqueous gel for selected diabetic lower-extremity ulcers.
• Its core excipient system uses sodium carboxymethylcellulose, sodium acetate, acetic acid, methylparaben, propylparaben, and water.
• Excipient value is concentrated in protein stability, rheology, preservative control, wound residence, and dosing accuracy.
• Original statutory exclusivity is expired, and broad original-product patent protection should not be assumed to remain commercially significant.
• The principal follow-on risks are a conventional abbreviated product, a 505(b)(2) reformulation, or a device-led product with improved dosing and packaging.
• Preservative-free unit-dose delivery and metered dosing are the clearest commercial white spaces.
• Manufacturing control of recombinant protein quality is a more important barrier than access to the basic excipients.
• Biosimilar terminology is less useful than "follow-on becaplermin" because REGRANEX was approved under an NDA rather than as a conventional modern biologic license.
• Current Orange Book listings and FDA application records should control any final patent or launch-timing decision.

FAQs

Can sodium carboxymethylcellulose be replaced in a REGRANEX follow-on product?

Yes, but replacement would require evidence that the new polymer provides comparable dose uniformity, protein stability, rheology, microbial quality, packaging compatibility, and clinical performance.

Would a preservative-free REGRANEX product be patentable?

Potentially. Patentability would be stronger if the product demonstrated an unexpected technical benefit, such as improved becaplermin potency retention, reduced aggregation, extended in-use stability, or lower wound irritation.

Is a becaplermin generic automatically therapeutically equivalent to REGRANEX?

No. FDA would determine the appropriate abbreviated pathway and equivalence requirements based on the product’s formulation, dosage form, active protein characteristics, and available reference-product data.

Which package is most suitable for a premium REGRANEX reformulation?

A sterile unit-dose syringe or metered applicator is the strongest candidate when it demonstrates lower product waste, controlled dosing, reduced contamination risk, and acceptable protein recovery.

What is the main commercial weakness of a REGRANEX reformulation?

The product addresses a specialized patient population and carries important safety and use restrictions. A reformulation must create measurable value in healing outcomes, workflow, adherence, or total treatment cost to justify development and premium pricing.

References

1. U.S. Food and Drug Administration. (2020). REGRANEX (becaplermin) gel, 0.01% prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: REGRANEX-becaplermin gel.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (n.d.). New drug application and marketing exclusivity provisions under the Federal Food, Drug, and Cosmetic Act.